SentiSearch, Inc. (SSRC)

[e-ore]

This, from the SSRC website, is a great summary of the possibilities. There is a lot of research being done in this field. Bayer Crop Science chose Sentisearch as a partner over all the others, and Bayer AG chose to feature the agreement with SSRC as one of 16 "Highlights of 2010" in their annual report. The Bill and Melinda Gates foundation renewed the $5 million grant for Dr Axel's research after SSRC and Bayer Crop Science entered into the 2 year research and product development agreement. Please refer to the ibox here for further information. So many startup companies offer promises and hope. The connections here are impressive, real, and verifiable. Will the research bear fruit? We'll have to wait and see :)

http://www.sentisearch.com/

SentiSearch has obtained an exclusive worldwide license in certain intellectual property from the Trustees of Columbia University in the City of New York. In addition, we possess our own patents and patent applications.

The Company’s intellectual property assets are primarily based on the work of Dr. Richard Axel, who was awarded the 2004 Nobel Prize in Medicine, and who is a Scientific Consultant to the Company.

With an extension of funding to Columbia from the Foundation for the National Institutes of Health (FNIH) through the Grand Challenges in Global Health Initiative of the Bill and Melinda Gates Foundation, SentiSearch has continued to maximize the potential of Dr. Axel’s work. In 2010, SentiSearch and Bayer CropSciences entered into a research and development agreement to screen Bayer’s extensive library of compounds in a search for the identification of new molecules targeting odorant receptors in insects.

This collaboration includes work performed in Professor Axel’s laboratory at Columbia University funded through the Grand Challenges in Global Health Initiative. One of the main goals of this initiative is to improve the control of insects that affect human health, with the ultimate eradication of malaria, dengue fever, and other insect-borne diseases in the developing world.

In addition to possible benefits in the field of public health, our activities with Bayer could also result in innovative products with a new mode of action capable of preventing damage to agricultural crops caused by insects.

In addition, we continue to explore other commercial applications of our intellectual property assets, including in mosquito repellents to be sold by household product companies, as well as applications in the areas of food production and pharmaceuticals.